NCT04753216
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +23 more
- Locations
-
- Northwestern University Chicago, Illinois, United States
Clinical trial condition
Platinum-Resistant Fallopian Tube Carcinoma
Explore clinical trials studying Platinum-Resistant Fallopian Tube Carcinoma. Study availability and eligibility vary by location and protocol.
18 public trials
4 recruiting studies
Platinum-Resistant Fallopian Tube Carcinoma trial results
Active, Not Recruiting
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT05465941
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +20 more
- Locations
-
- Mayo Clinic Rochester, Minnesota, United States
Active, Not Recruiting
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
NCT04616534
- Conditions
- Adnexal Diseases, Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, +40 more
- Locations
-
- National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
Active, Not Recruiting
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
NCT02650986
- Conditions
- Adnexal Diseases, Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, +78 more
- Locations
-
- Roswell Park Cancer Institute Buffalo, New York, United States
Active, Not Recruiting
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03587311
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, +5 more
- Locations
-
- UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
- UCHealth University of Colorado Hospital Aurora, Colorado, United States
- UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida, United States
Active, Not Recruiting
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
NCT05271318
- Conditions
- Adenoviridae Infections, DNA Virus Infections, Infections, +10 more
- Locations
-
- Mayo Clinic Rochester, Minnesota, United States
- Northwell Heatlh/Lenox Hill Hospital New York, United States
- Docrates Cancer Center Helsinki, Finland
Active, Not Recruiting
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04781088
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +24 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
- Allegheny Health Network Pittsburgh, Pennsylvania, United States
Active, Not Recruiting
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT03907527
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +48 more
- Locations
-
- National Institutes of Health (NIH) Bethesda, Maryland, United States
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States